Project description
Advancing personalised cancer therapy
Tumours release fragments of DNA into the bloodstream while they grow and divide. This circulating tumour DNA (ctDNA) can be detected and analysed in clinical practice, usually via liquid biopsy, to provide valuable information about the tumour's genetic characteristics. Funded by the HORIZON programme, the GUIDE.MRD project aims to standardise and validate ctDNA diagnostics for clinical use. The project will involve regulatory authorities to provide evidence-based recommendations and guidelines for utilising ctDNA tests to guide multi-modal therapies in cancer patients following surgery. Protocols for ctDNA analysis and interpretation across different cancer types will support personalised treatments for enhanced patient outcomes.
Objective
Advancing personalized approaches in cancer therapy, aiding identification and adaptation of multi-modal treatment strategies for improved outcomes depends on clinical implementation of novel diagnostic technologies. For most cancer types the risk-features used to select individuals for post-operative adjuvant multimodal therapy are suboptimal, where many patients are overtreated and others undertreated. Liquid biopsy has opened a new diagnostic avenue to detect and monitor minimal residual disease (MRD) in individual cancer patients, especially for selecting patients for multi-modal therapies post-operatively. However, despite many circulating tumor DNA (ctDNA) diagnostics being developed there is a lack of standardization, harmonization, and robust data to demonstrate clinical validity. GUIDE.MRD is a consortium of leading academics, technology companies, pharmaceutical companies, and experts in multi-stakeholder engagements. Together, we will tackle the critical questions by developing reference standards for ctDNA diagnostics, clinically validate promising ctDNA diagnostics and develop data to guide the use of multi-modal therapies with a non-invasive diagnostic test. With robust engagement with regulatory authorities, payers and importantly patients themselves, we will develop recommendations and guidelines based on objective data to use ctDNA diagnostics to guide multi-modal therapy selection to improve patient outcomes.
Fields of science
Keywords
Programme(s)
- HORIZON.2.1 - Health Main Programme
- HORIZON.2.1.7 - Innovative Health Initiative
Funding Scheme
HORIZON-JU-RIA - HORIZON JU Research and Innovation ActionsCoordinator
20251 Hamburg
Germany
See on map
Participants (22)
8000 Aarhus C
See on map
9713 GZ Groningen
See on map
06003 Nice
See on map
28029 Madrid
See on map
22927 Grosshansdorf
See on map
17177 Stockholm
See on map
CB21 6DF Great Abington
See on map
CB25 9TL Cambridge
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
01757 MILFORD MA
See on map
1050 Bruxelles / Brussel
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1040 Bruxelles / Brussel
See on map
6300 Zug
See on map
10154 New York
See on map
4070 Basel
See on map
53100 Siena
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
CB2 0AA Cambridge
See on map
8010 Graz
See on map
1050 Bruxelles / Brussel
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
032266 Bucharest
See on map
34000 Montpellier
See on map
8200 Aarhus
See on map
104 22 Stockholm
See on map
Partners (1)
3008 Bern
See on map